首页 | 本学科首页   官方微博 | 高级检索  
检索        


Pneumococcal vaccination coverage among adults newly diagnosed with underlying medical conditions and regional variation in the U.S.
Institution:1. Odysseus Data Services, Inc., 245 First St, Cambridge, MA, USA;2. Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033 USA
Abstract:BackgroundThe Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices recommends pneumococcal vaccination for adults with chronic or immunocompromising conditions to prevent pneumococcal disease, yet vaccination rates are low and have limited information on regional variation. This study examines factors associated with pneumococcal vaccination in adults with underlying conditions and describes regional variation in vaccination across the U.S.MethodsUsing IBM MarketScan Commercial Database and Medicare Supplemental Database, this retrospective cohort study included adults ages 19–64 newly diagnosed with chronic (i.e. diabetes, chronic heart, lung, or liver disease, alcohol or tobacco dependence) or immunocompromising (i.e. cancer, chronic renal disease, organ transplant, HIV/AIDS, and asplenia) conditions in 2013. Adults were followed up until the time of pneumococcal vaccination, death, or December 31, 2019, whichever came first. Cox proportional hazards model was used to examine factors associated with vaccination. Vaccination rate was calculated by metropolitan statistical area (MSA) and visually represented on a U.S. map.Results255,330 adults were included. Vaccination rate increased from 6.0% to 21.1% among adults with one year and five years of follow-up, respectively. It took 2.4 years on average for adults to receive vaccination after initial diagnosis. Adults ages 50–64, 35–49 (relative to 19–34) or receiving influenza vaccination were more likely to receive pneumococcal vaccinations. Adults with HIV/AIDS were more likely and those with other conditions were less likely to be vaccinated than those with diabetes. Adults being diagnosed by other providers were less likely to be vaccinated than those diagnosed by primary care providers. Vaccination rate varied largely across MSAs, ranging from 0.0% (Ames, IA; Cheyenne, WY) to 34.0% (Ann Arbor, MI).ConclusionPneumococcal vaccination remains low and most adults with underlying conditions are unvaccinated. Insights into factors associated with vaccination, including regional variability, can help to increase pneumococcal vaccination.
Keywords:Pneumococcal vaccination coverage  Adults  Underlying medical conditions  Regional variation  CDC"}  {"#name":"keyword"  "$":{"id":"k0030"}  "$$":[{"#name":"text"  "_":"Centers for Disease Control and Prevention  ACIP"}  {"#name":"keyword"  "$":{"id":"k0040"}  "$$":[{"#name":"text"  "_":"Advisory Committee on Immunization Practices  PPSV23"}  {"#name":"keyword"  "$":{"id":"k0050"}  "$$":[{"#name":"text"  "_":"Pneumococcal Polysaccharide Vaccine  23-Valent  PCV13"}  {"#name":"keyword"  "$":{"id":"k0060"}  "$$":[{"#name":"text"  "_":"Pneumococcal Conjugate Vaccine  13-valent  FDA"}  {"#name":"keyword"  "$":{"id":"k0070"}  "$$":[{"#name":"text"  "_":"Food and Drug Administration  PCV15"}  {"#name":"keyword"  "$":{"id":"k0080"}  "$$":[{"#name":"text"  "_":"Pneumococcal Conjugate Vaccine  15-valent  PCV20"}  {"#name":"keyword"  "$":{"id":"k0090"}  "$$":[{"#name":"text"  "_":"Pneumococcal Conjugate Vaccine  20-valent  HIV/AIDS"}  {"#name":"keyword"  "$":{"id":"k0100"}  "$$":[{"#name":"text"  "_":"Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome  ICD-9-CM"}  {"#name":"keyword"  "$":{"id":"k0110"}  "$$":[{"#name":"text"  "_":"International Classification of Diseases  Ninth Revision  Clinical Modification  NDC"}  {"#name":"keyword"  "$":{"id":"k0120"}  "$$":[{"#name":"text"  "_":"National Drug Codes  CPT4"}  {"#name":"keyword"  "$":{"id":"k0130"}  "$$":[{"#name":"text"  "_":"Current Procedural Terminology version 4  MSA"}  {"#name":"keyword"  "$":{"id":"k0140"}  "$$":[{"#name":"text"  "_":"Metropolitan statistical area  HMO"}  {"#name":"keyword"  "$":{"id":"k0150"}  "$$":[{"#name":"text"  "_":"Health Maintenance Organization  PPO"}  {"#name":"keyword"  "$":{"id":"k0160"}  "$$":[{"#name":"text"  "_":"Preferred Provider Organization  EPO"}  {"#name":"keyword"  "$":{"id":"k0170"}  "$$":[{"#name":"text"  "_":"Exclusive Provider Organization  POS"}  {"#name":"keyword"  "$":{"id":"k0180"}  "$$":[{"#name":"text"  "_":"Point-of-service  CDHP"}  {"#name":"keyword"  "$":{"id":"k0190"}  "$$":[{"#name":"text"  "_":"Consumer-Driven Health Plan  HDHP"}  {"#name":"keyword"  "$":{"id":"k0200"}  "$$":[{"#name":"text"  "_":"High Deductible Health Plan
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号